| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| dostarlimab rectal cancer nejm | 1.96 | 0.7 | 9034 | 72 | 30 |
| dostarlimab | 1.68 | 0.2 | 1128 | 13 | 11 |
| rectal | 0.45 | 0.7 | 3162 | 75 | 6 |
| cancer | 0.25 | 0.8 | 145 | 44 | 6 |
| nejm | 0.59 | 0.1 | 5949 | 79 | 4 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| dostarlimab rectal cancer nejm | 0.62 | 0.8 | 8400 | 100 |
| dostarlimab and rectal cancer | 1.51 | 0.9 | 2582 | 82 |
| dostarlimab rectal cancer trial | 1.97 | 0.2 | 7036 | 10 |
| rectal cancer drug trial dostarlimab | 1.94 | 0.8 | 4694 | 76 |
| dostarlimab rectal cancer fda | 1.78 | 0.1 | 5870 | 59 |
| dostarlimab endometrial cancer nejm | 0.44 | 0.2 | 3266 | 14 |
| dostarlimab trial colorectal cancer | 0.58 | 0.5 | 8144 | 7 |
| dostarlimab colon cancer trial | 0.09 | 0.8 | 7439 | 96 |
| dostarlimab for colorectal cancer | 0.08 | 1 | 3902 | 89 |
| tnt rectal cancer nejm | 0.91 | 0.6 | 1260 | 3 |
| dostarlimab clinical trials colon cancer | 0.11 | 0.7 | 4242 | 5 |
| immunotherapy rectal cancer nejm | 1.58 | 0.9 | 9059 | 92 |
| dostarlimab for colon cancer | 1.52 | 0.5 | 3104 | 57 |
| new england journal of medicine rectal cancer | 1.77 | 0.5 | 207 | 7 |
| dostarlimab and prostate cancer | 0.79 | 0.6 | 7364 | 59 |
| wales dostarlimab rectal cancer | 0.45 | 0.1 | 3697 | 37 |
| dostarlimab fda approval colon cancer | 0.32 | 0.2 | 8904 | 96 |
| dostarlimab for pancreatic cancer | 1.63 | 0.8 | 6404 | 77 |
| dostarlimab and endometrial cancer | 1.01 | 0.3 | 195 | 75 |
| dostarlimab new england journal of medicine | 1.8 | 0.7 | 1430 | 83 |
